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Abstract The binding properties of Caragana arborescens
agglutinin (CAA, pea tree agglutinin) were studied by enzyme
linked lectinosorbent assay (ELLSA) and by inhibition of CAA-
glycan interaction. Among glycoproteins (gps) tested, CAA
reacted strongly with asialo bird nest gp, asialo rat sublingual gp,
human Tamm-Horsfall Sd(a+) urinary gp (THGP) and asialo
THGP that are rich in GalNAcK1C, GalNAcL1C and/or
GalL1C4GlcNAc residues. CAA also bound tightly with multi-
valent GalL1C4GlcNAc (mII) containing glycoproteins (human
blood group precursor gps, asialo fetuin) and asialo ovine
salivary glycoprotein (Tn, GalNAcK1CSer/Thr), but CAA
reacted poorly or not at all with sialylated glycoproteins tested.
Of the sugars tested for inhibition of binding, Forssman
pentasaccharide (Fp, GalNAcK1C3GalNAcL1C3GalK1C
4GalL1C4Glc) was the best. It was about 2.3, 9.5 and 52.6
times more active than GalL1C4GlcNAc, GalNAc and Gal,
respectively, and about 1.9 times more active than tri-antennary
GalL1C4GlcNAc (Tri-II). These results suggest that this
agglutinin is mainly specific for Fp, mII and Tn clusters. This
property can be used to detect human abnormal glycotopes
related to Fp and unmasked mII/Tn clusters and to study cell
growth and differentiation given the lack of toxicity of this lectin
toward mouse fibroblast cells.
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1. Introduction
The study of lectins is increasing due to their ever wider
importance in biology, immunology and medicine [1^3]. In the
early 1980s, lectins of the same apparent monosaccharide spe-
ci¢city were found to possess di¡erent reactivities toward dif-
ferent oligosaccharide chains [4^8], and to have di¡erential
a⁄nities for animal cells and mammalian glycoproteins [5^
9]. This implies that lectins have their own binding speci¢city
which extends beyond the monosaccharide unit. Indeed, many
lectins have broad spectra of binding properties and possess
dual or multiple a⁄nities for various disaccharides [5^7,10].
The lectin used for this study was puri¢ed from the pea
tree, Caragana arborescens (CAA). It is a glycoprotein with
high hemagglutinating activity [11]. It is composed of two
polypeptides with apparent molecular weight near 30 000. In
the middle of the 1970s, the biochemical property of CAA has
been well characterized [11]. However, the combining site of
this lectin has not yet been fully determined. In order to
understand better the biological roles of CAA and for it to
be useful as an investigative tool for biomedical and immu-
nochemical studies, it is important to establish its carbohy-
drate binding properties. In the present report, the carbohy-
drate speci¢city of CAA was studied by enzyme linked
lectinosorbent assay (ELLSA) and by inhibition of lectin-gly-
coprotein binding. The results show that this lectin strongly
recognizes exposed GalNAcK1C3GalNAc (F), multi-valent
GalL1C4GlcNAc (mII) and cluster forms of GalNAcK1CS-
er/Thr (Tn) glycotopes, especially Forssman pentasaccharide.
2. Materials and methods
2.1. Lectin
C. arborescens agglutinin (CAA) was purchased from Sigma Chem-
ical Company (St. Louis, MO, USA).
2.2. Glycoproteins and polysaccharide
Cyst human blood group active glycoproteins (MSS, Mcdon, Tighe
and Beach) were prepared from human ovarian cyst £uid as described
previously [12^15]. Ovine and rat salivary glycoproteins were puri¢ed
according to the method of Tettamanti and Pigman [16] and its mod-
i¢cation [17^19]. The crude salivary gland mucus glycoprotein (native
BN) of the Chinese swiftlet (genus Collocalia) was extracted at 66‡C
with distilled H2O for 20 min from commercial bird nest (BN) [20,21].
Tamm-Horsfall glycoprotein, which was kindly provided by Dr.
W.M. Watkins, University of London, Royal Postgraduate Medical
School, Hammersmith Hospital, London, UK, was isolated from the
urine of one single donor (W.T.J.M.) with Sd(a) blood group by the
method of Tamm and Horsfall [22] with 0.58 M NaCl. The precipi-
tated material was lyophilized, its lipid content removed with 9:1, 2:1
and 1:2 chloroform-methanol treatment, and further puri¢ed as de-
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Abbreviations: gp, glycoprotein; THGP, Tamm-Horsfall glycopro-
tein; BN, bird nest glycoprotein; OSM, ovine submandibular glyco-
protein (major); RSL, rat sublingual glycoprotein (major); ELLSA,
enzyme linked lectinosorbent assay; Sugars: Gal, D-galactopyranose;
Glc, D-glucopyranose; LFuc, L-fucopyranose; GalNAc, 2-acetamido-
2-deoxy-D-galactopyranose; GlcNAc, 2-acetamido-2-deoxy-D-gluco-
pyranose; Lectin: CAA, Caragana arborescens agglutinin; Applied
lectin determinants [36^38]: Fp, GalNAcK1C3GalNAc L1C3Gal
K1C4GalL1C4Glc; II, GalL1C4GlcNAc; mII, poly(multi)valent
II, including bi-, tri- and tetra-antennary and cluster form of II;
Tn, GalNAcK1CSer/Thr.
Tri-II, tri-antennary GalL1C4GlcNAc:
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scribed [22]. Fetuin and mannan were purchased from Sigma Chem-
ical Co. (St. Louis, MO, USA).
For desialylation, a glycoprotein sample in 0.01 N HCl was hydro-
lyzed at 80‡C for 90 min and dialyzed against distilled H2O [16,23]. A
cyst P-1 glycoprotein (Cyst Mcdon P-1) was the non-dialyzable frac-
tion of the cyst gp after hydrolysis in pH 1.5 at 100‡C for 2 h [12^15].
2.3. Sugars used as inhibitors
Monosaccharides, their derivatives and most oligosaccharides were
purchased from Sigma Chemical Company (St. Louis, MO, USA) and
GalNAcK1C3GalNAcL1C3GalK1C4GalL1C4Glc (Fp) was from
Accurate Chemical and Scienti¢c Corporation (Westbury, NY, USA)
Tri-antennary GalL1C4GlcNAc glycopeptides and Tn glycopep-
tides were prepared from asialo fetuin and asialo OSM respectively.
The procedures were as described previously [24,25].
2.4. Lectinochemical assays
The assay was performed according to the procedures described by
Fig. 1. Binding of CAA to microtiter plates coated with serially diluted glycoproteins. The lectin was used at a constant amount of 20 ng/well.
Total volume 50 Wl. A405 was read at 2 h.
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Duk et al. [26]. The volume of each reagent applied to the plate was
50 Wl/well, and all incubations, except for coating, were performed at
room temperature. The reagents, if not indicated otherwise, were di-
luted with TBS containing 0.05% Tween 20 (TBS-T). The TBS bu¡er
or 0.15 M NaCl containing 0.05% Tween 20 was used for washing the
plate between incubations.
For inhibition studies, the serially diluted inhibitor samples were
mixed with an equal volume of lectin solution containing a ¢xed
amount of CAA. The control lectin sample was diluted two-fold
with TBS-T. After 30 min at room temperature, the samples were
tested by the binding assay, as described by Duk et al. [25,26]. The
inhibitory activity was estimated from the inhibition curve and is ex-
pressed as the amount of inhibitor (nmol/well) giving 50% inhibition
of the control lectin binding.
3. Results
3.1. CAA-glycoform interaction
The interaction patterns of CAA with glycoproteins, as
studied by a microtiter plate lectin-enzyme binding assay
(ELLSA), are illustrated in Fig. 1 and its binding pro¢le
with glycoproteins is shown in Table 1. Among glycoproteins
tested, CAA reacted strongly with most GalNAcK/LC and
GalL1C4GlcNAc containing glycoproteins. These include
asialo bird nest glycoprotein (BN) (Fig. 1a), asialo rat sublin-
gual gp (Fig. 1b), human blood group precursor equivalent
gps (cyst Mcdon P-1 and MSS 1st Smith degraded, Fig. 1c;
cyst Tighe P-1 and Beach P-1, Fig. 1d), native Tamm-Horsfall
Sd(a) glycoprotein and its asialo product (Fig. 1e) and asialo
fetuin (Fig. 1f). They reached absorbance values at 405 nm
over 1.7 within 2 h, but were inactive with most sialic acid
containing and blood group A, B, H active glycoproteins. To
overcome the possible problem of lack of quantitation of gly-
coproteins absorbed onto the microwells, the inhibitory
powers of these glycoproteins were examined and described
in the next section.
3.2. Inhibition of CAA-glycoform interaction by various
glycoproteins
The abilities of various glycoproteins to inhibit the binding
Fig. 2. Inhibition of CAA binding to cyst Mcdon P-1 gp coated
plates with various glycoproteins. The quantity of cyst Mcdon P-1
glycoprotein used to coat was 12.5 ng per well. The amount of lec-
tin used for the inhibition assay was 20 ng per well. Total volume:
50 Wl. A405 was read at 2 h. (a) Salivary gps, urinary gp and fetuin;
(b) human ovary cyst gps.
Fig. 3. Inhibition of CAA binding to cyst Mcdon P-1 gp coated
ELLSA plates with monosaccharides, and oligosaccharides. Condi-
tions as in Fig. 2. (a) Monosaccharides and their derivatives; (b)
mammalian oligo- and disaccharides.
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of CAA with Mcdon P-1 were analyzed by ELLSA and
shown in Fig. 2. The amounts of glycoprotein (ng) required
for 50% inhibition are listed in Table 2.
Among the glycoproteins tested for inhibition of interac-
tion, asialo bird nest gp from Chinese swiftlet (Genus Collo-
calia) (curve 1), asialo rat sublingual gp (curve 2) and Mcdon
P-1, a mild acid hydrolyzed glycoprotein prepared from hu-
man ovarian cyst £uid (curve 3) were the best (Fig. 2a), which
required less than 7.0 ng to inhibit 50% of the interaction. All
other exposed GalL1C4GalNAc, GalNAcK or GalNAcL gly-
cotope containing glycoproteins also inhibited well the CAA-
Mcdon P-1 interaction (curves 4 to 9), while Cyst Tighe phe-
nol insoluble (blood group H and Leb active gp), RSL, fetuin
and native BN (curves 13 to 16) were inactive.
3.3. Inhibition of CAA-glycoform interaction by mono- and
oligosaccharides
The ability of various sugar ligands to inhibit the binding of
CAA with Mcdon P-1 as measured by ELLSA is shown in
Fig. 3 and the nmol of ligands required for 50% inhibition of
the lectin-glycan interaction are listed in Table 3.
Among the monosaccharides and oligosaccharides
studied, the Forssman pentasaccharide (Fp, GalNAcK1C
3GalNAcL1C3GalK1C4GalL1C4Glc) and p-NO2-phenyl
LGalNAc, (curves 1 and 2) were the best inhibitors, and about
1.9 and 2.3 times more active than Tri-antennary
GalL1C4GlcNAc, (Tri-II, curve 4 in Fig. 3b) and monomeric
GalL1C4GlcNAc (curve 5), respectively. Fp (curve 1) was 9.5
and 52.6 times more active than GalNAc (curve 11) and Gal
Table 1
Binding of CAA to human blood group A, B, H, Ii and Leb active glycoproteins(gps), sialo and asialo glycoproteins by ELLSAa
Order of
activities
Curve in
Fig. 1
Glycoprotein (lectin determinantsb ; blood group speci¢city) Maximum A405
absorbance
Binding
intensityc
1 a Asialo bird nest gp (II, E, T, FK) 2.5 +++++
2 b Asialo RSL (II) 2.5 +++++
3 c Cyst Mcdon P-1 (T, Tn, I, II) 2.6 +++++
4 e Asialo THGP Sd(a) 3.0 +++++
5 e Tamm-Horsfall urinary glycoproteins Sd(a) (THGP) 2.8 +++++
6 f Asialo fetuin (II, T) 2.5 +++++
7 b Asialo OSM (Tn) 2.4 ++++
8 d Cyst Tighe P-1 (I, II) 2.2 ++++
9 c Cyst MSS 1st Smith degraded (T, Tn, I, II) 1.8 +++
10 d Cyst Beach P-1 (T, Tn, I, II) 1.7 +++
11 c Cyst Mcdon (Ah) 0.5 +
12 d Cyst Beach phenol insoluble (B) 0.4 +
13 c Cyst MSS 2U(Ah[A1]) 0.3 +
14 a Bird nest gp (BN, Sialyl II, E, T, F) 0.3 +
15 f Fetuin (Sialyl II, T) 0.07 3
16 d Cyst Tighe phenol insoluble (H, Leb) 0.06 3
17 b Rat sublingual major gp (RSL, Sialyl II) 0.02 3
18 b Ovine salivary gp (OSM, Sialyl Tn) 0.01 3
aTwenty ng of biotinylated lectin was added to various concentrations of glycoprotein ranging from 0.12 ng to 10 Wg.
bThe symbol in parentheses indicates the human blood group activity (Table 2) and/or lectin determinants [4^6]: F, GalNAcK1C3GalNAc; A,
GalNAcK1C3Gal; Ah, GalNAcK1C3[LFucK1C2] Gal; B, GalK1C3Gal; E, GalK1C4Gal; T, GalL1C3GalNAc; Tn, GalNAcK1CSer/
Thr; I/II, GalL1C3/4GlcNAc; L, GalL1C4Glc.
cThe results were interpreted according to the spectrophotometric absorbance value at 405 nm (i.e. OD405) after 2 h incubation as follows:
+++++, ODv 2.5; ++++, 2.5sODv 2.0; +++, OD: 1.9^1.5; ++, OD: 1.5^0.75; +, OD: 0.75^0.2; and 3, OD: 6 0.2.
Table 2
Amount of glycoproteins giving 50% inhibition of binding of CAA (20 ng/50 Wl) by Cyst Mcdon P-1 gp (12.5 ng/50 Wl)a
Order of
activities
Curve in
Fig. 2
Inhibitor Quantity giving
50% inhibition (ng)
Reciprocal of
relative potencyb
1 a Asialo bird nest gp (II, E, T, FK) 3.1 1774.3
2 a Asialo RSL (II, Tn) 6.5 846.2
3 b Cyst Mcdon P-1 (T, Tn, I, II) 7.0 785.7
4 b Cyst Tighe P-1 (I/II[Ii]) 12.0 458.3
5 b Cyst Beach P-1 (T, Tn, I, II) 18.0 305.6
6 a Asialo OSM (Tn) 20.0 27.5
7 b Cyst MSS 1st Smith degraded (T, Tn, I, II) 95.0 57.8
8 a THGP Sd(a) 100.0 55.0
9 b Cyst Mcdon (Ah) 210.0 26.2
10 b Cyst MSS 10% 2Uppt (Ah[A1]) 250.0 22.0
11 a, b GalNAc 1.5U103 3.7
12 a, b Gal 5.5U103 1
13 b Cyst Tighe phenol insoluble (H, Leb) 12.3% (s 555.6)
14 a RSL (Sialyl II) 6.2% (s 555.6)
15 a Fetuin (Sialyl II, T) 4.2% (s 277.8)
16 a Native bird nest gp (Sialyl II, E, T, F) 3.5% (s 277.8)
aThe inhibitory activity was estimated from the inhibition curve in Fig. 2 and is expressed as the amount of inhibitor giving 50% inhibition of
the control lectin binding. Total volume 50 Wl.
bReciprocal of relative potency of sugars when Gal was taken as 1.0 [10].
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(curve 16), respectively, while GalNAcL1C3Gal-OMe and
GalNAc (curves 10 and 11) were equally active.
GalL1C4GlcNAc (II) was slightly more active than
GalL1C4Glc (L) (curve 5 vs. curve 6). p-NO2-phenyl deriva-
tives of Gal were about 1.7 times more active than the corre-
sponding methyl derivatives (curve 7 vs. 13, 8 vs. 14 in Fig.
3a) indicating that hydrophobicity contributes somewhat in
the binding. Man was tested up to 100U greater concentra-
tion than Gal, but was still inactive (negative control).
4. Discussion
In this report, we studied the binding reactivity of CAA by
using our recently established ELLSA method, in which the
lectin was biotinylated and binding was detected with alkaline
phosphatase conjugated avidin [26]. To avoid the possible
problem created by di¡erences in immobilization of the gly-
coproteins on the microplate wells, the reactivities of the gly-
coproteins used in Fig. 1 (Table 1), were also tested for in-
hibitory power of lectin-glycoprotein binding (Fig. 2 and
Table 2). Another purpose of this study was to examine the
inhibition of lectin binding with a variety of well de¢ned oli-
gosaccharides in solution. The conclusions of this study indi-
cate that (1) GalNAcK1C3GalNAc and complex
GalL1C4GlcNAc containing glycoproteins bind strongly to
CAA (Figs. 1 and 2 and Tables 1 and 2); (2) when the in-
hibitory reactivities of CAA-glycoprotein binding by mono-
and oligosaccharides were compared, it was shown that Fors-
sman pentasaccharide is the most potent inhibitor; (3) the p-
NO2-phenyl derivatives of Gal were more active than the
corresponding methyl derivatives (curves 7 vs. 13 and 8 vs.
14 in Fig. 3a), indicating that hydrophobic forces are impor-
tant for binding (Table 3); (4) the combining site of CAA
should be a shallow type or groove (Table 3), as this lectin
is able to accommodate the monosaccharide at the non-reduc-
ing end of an oligosaccharide, Tn determinants, and probably
internal GalNAcL1C ; and (5) its binding a⁄nity toward
mammalian structural features can be ranked in decreasing
order as follows: FpvTri-II and cluster forms of IIvLs
GalNAcsEs IsGal.
Both Tn determinant and Fp glycotopes are considered as
markers for cancerous tissues [27^29]. The unusual enhance-
ment of activity of F and Tn has been strongly associated with
carcinogenesis [28,29].
The CAA-glycan pro¢le obtained by this study can be used
to detect human abnormal glycotopes related to Fp and un-
masked mII/Tn clusters and to study cell growth and di¡er-
entiation given the lack of toxicity of this lectin toward mouse
¢broblast cells.
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